Payment overview · 2025
General Payments
$226.41
11 reported records · 7 companies
Healthcare provider profile · identity verified
Alyssa Webb
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WINFIELD, AL · NPI 1538543145
Verified facts
What the public records show
CMS Open Payments records show Alyssa Webb received $226.41 in general payments during 2025 across 11 reported records.
Sumitomo Pharma America, Inc. accounted for 45.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $102.07 | 45.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.80 | 18.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.99 | 10.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.26 | 7.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.79 | 6.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.29 | 6.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.21 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.41 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $102.07 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 158 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 53 |
| Omeprazole | Omeprazole | 114 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 41 |
| Potassium Chloride | Potassium Chloride | 89 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 34 |
| Montelukast Sodium | Montelukast Sodium | 83 | 40 |
| Famotidine | Famotidine | 79 | 37 |
| Furosemide | Furosemide | 79 | 39 |
| Losartan Potassium | Losartan Potassium | 78 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 28 |
| Lisinopril | Lisinopril | 73 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 27 |
| Mounjaro | Tirzepatide | 67 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 28 |
| Lovastatin | Lovastatin | 60 | 28 |
| Farxiga | Dapagliflozin Propanediol | 59 | 24 |
| Sertraline Hcl | Sertraline Hcl | 56 | 21 |
| Alendronate Sodium | Alendronate Sodium | 53 | 25 |
| Trazodone Hcl | Trazodone Hcl | 50 | 25 |
| Glipizide Er | Glipizide | 48 | 23 |
| Metformin Hcl Er | Metformin Hcl | 47 | 23 |
| Carvedilol | Carvedilol | 46 | 20 |
| Fluconazole | Fluconazole | 46 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 18 |
| Methocarbamol | Methocarbamol | 44 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 17 |
| Ozempic | Semaglutide | 41 | 13 |
| Chlorthalidone | Chlorthalidone | 40 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 16 |
| Buspirone Hcl | Buspirone Hcl | 38 | 19 |
| Eliquis | Apixaban | 37 | 13 |
| Celecoxib | Celecoxib | 36 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 13 |
| Amoxicillin | Amoxicillin | 34 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 11 |
| Meloxicam | Meloxicam | 34 | 16 |
| Jardiance | Empagliflozin | 33 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Metformin Hcl | Metformin Hcl | 31 | 18 |
| Allopurinol | Allopurinol | 30 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 17 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | 11 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Estradiol | Estradiol | 25 | 11 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 21 |
| Donepezil Hcl | Donepezil Hcl | 24 | 14 |
| Azithromycin | Azithromycin | 23 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | 15 |
| Mirtazapine | Mirtazapine | 21 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | 12 |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Nabumetone | Nabumetone | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.41 · 11 records | Sumitomo Pharma America, Inc. | Cologuard Collection Kit, GEMTESA, Kerendia, VRAYLAR, Wegovy, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error